The well-named disease modifying drugs have been very successful in treating the inflammation of rheumatoid arthritis. Could they be successful in treating the inflammation and associated pain of osteoarthritis? We conducted 2 large randomised UK trials, using hydroxychloroquine in hand osteoarthritis and methotrexate in knee osteoarthritis. Professor Philip Conaghan, Director of our Leeds University arthritis Institute and Deputy Director of our BRC, will present the findings of these studies and discuss what we have learnt.
The event will take place on Thursday 30th May 2019, 12.30-2.30pm and then repeated at 6-8pm at the NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA
A buffet lunch/dinner is provided, so please do mention any dietary requirements when booking your place.
For more information and booking, please contact Amy Rebane on (0113) 3924485 or firstname.lastname@example.org